menu
    • menu
    [{"orgOrder":0,"company":"Napo EU","sponsor":"Atlas Sciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"NP-500","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Napo EU \/ Atlas Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ Atlas Sciences"},{"orgOrder":0,"company":"Napo EU","sponsor":"Oasis Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Crofelemer","moa":"Anoctamin-1","graph1":"Gastroenterology","graph2":"Approved","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Napo EU \/ Oasis Capital","highestDevelopmentStatusID":"12","companyTruncated":"Napo EU \/ Oasis Capital"},{"orgOrder":0,"company":"Napo EU","sponsor":"Jaguar Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Crofelemer","moa":"CFTR\/CaCC","graph1":"Gastroenterology","graph2":"Approved","graph3":"Napo EU","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"delayed-release tablet","sponsorNew":"Napo EU \/ Napo","highestDevelopmentStatusID":"12","companyTruncated":"Napo EU \/ Napo"},{"orgOrder":0,"company":"Napo EU","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Napo EU \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ Not Applicable"},{"orgOrder":0,"company":"Napo EU","sponsor":"Quadri Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Crofelemer","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Napo EU \/ Quadri Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ Quadri Pharmaceuticals"},{"orgOrder":0,"company":"Napo EU","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Napo EU \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Napo EU \/ Not Applicable"},{"orgOrder":0,"company":"Napo EU","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Napo EU \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Napo EU \/ Not Applicable"},{"orgOrder":0,"company":"Napo EU","sponsor":"Jaguar Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Napo EU \/ Jaguar Health","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ Jaguar Health"},{"orgOrder":0,"company":"Napo EU","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Crofelemer","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Napo EU \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Napo EU \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Napo EU

    Menu

    Napo EU

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Napo EU

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Napo EU

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Jaguar Health Submits Breast Cancer Therapy Diarrhea Impact Study Abstract

                            Details : Mytesi (crofelemer) is a CFTR/CaCC inhibitor small molecule drug administered orally as a delayed release tablet, for prophylaxis of diarrhea in cancer patients.

                            Brand Name : Mytesi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 08, 2024

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Napo EU

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Napo EU

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Jaguar Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Jaguar Submits Clinical Trial Applications for Crofelemer in Rare Diseases

                            Details : The company submitted a CTA to the Italian and German health authorities to initiate a phase 2 trial of Mytesi (crofelemer) for the treatment of short bowel syndrome with intestinal failure in adults.

                            Brand Name : Mytesi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 09, 2024

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Jaguar Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Napo EU

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Napo EU

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Jaguar Submits Orphan Drug Designation Application for Crofelemer

                            Details : Crofelemer is a plant-based drug extracted from red bark sap, being developed for treating moderate-to-severe diarrhea from various infections, including Vibrio cholerae.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 12, 2024

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Napo EU

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Napo EU

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of...

                            Details : Mytesi (crofelemer) is a CFTR/CaCC inhibitor small molecule drug administered orally as a delayed release tablet, for prophylaxis of diarrhea in cancer patients.

                            Brand Name : Mytesi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 11, 2023

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Napo EU

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Napo EU

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Quadri Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Jaguar Health Enters Exclusive Crofelemer Revenue Sharing License and Commercialization Agreement with Quadri ...

                            Details : Under the agreement, Napo grants Quadri Pharma exclusive promotional, commercialization, and distribution rights for a powder formulation of Mytesi (crofelemer), the only oral FDA-approved prescription drug under botanical guidance, for oral solution.

                            Brand Name : Mytesi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 02, 2023

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Quadri Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Napo EU

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Napo EU

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) A...

                            Details : Mytesi (crofelemer) powder for oral solution inhibits both cAMP-stimulated CFTR chloride ion channel and the CaCC at the luminal membrane of enterocytes, which being investigated for the treatment of microvillus inclusion disease.

                            Brand Name : Mytesi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 09, 2023

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Napo EU

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Napo EU

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Recipient : Jaguar Health

                            Deal Size : $5.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Jaguar Health Inks $5 M Non-dilutive Financing Involving Sale of Royalty Rights of Mytesi COVID-related Indica...

                            Details : Mytesi, only oral plant-based prescription medicine approved under FDA Botanical Guidance, is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit ...

                            Brand Name : Mytesi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 09, 2021

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Recipient : Jaguar Health

                            Deal Size : $5.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Napo EU

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Napo EU

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Oasis Capital

                            Deal Size : $2.3 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Third Amendment to Purchase Agreement with ...

                            Details : Oasis agreed to purchase additional accounts receivable of the Company related to the sales of the Company's Mytesi® drug product to Cardinal Health for the period of August 11, 2020 through September 3, 2020.

                            Brand Name : Mytesi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 10, 2020

                            Lead Product(s) : Crofelemer

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Oasis Capital

                            Deal Size : $2.3 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Napo EU

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed

                            Napo EU

                            Italy arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NP-500

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Atlas Sciences

                            Deal Size : $1.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Jaguar Health Enters Deal with Atlas Sciences to Develop NP-500, a Jaguar Non-Core Plant-based Type II Diabete...

                            Details : Under the the license, Jaguar has to initiate Phase 2 study of NP-500 under an investigational new drug application with the U.S. FDA or an IND-equivalent dossier within six months of April 15, 2020.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 16, 2020

                            Lead Product(s) : NP-500

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Atlas Sciences

                            Deal Size : $1.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth